Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs), natural killer (NK) cell, and gene modified NK Chimeric Antibody Receptor (CAR) therapies, with Companion Diagnostics. We have entered into collaborations with the leading research organizations to develop novel targets and next-generation assets. Our senior leaders are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.
The Company is based in Cambridge, Massachusetts, with European facilities in Munich, Germany.